Livin expression is an independent factor in rectal cancer patients with or without preoperative radiotherapy

Ding, Zhenyu; Zhang, Hong; Adell, Gunnar; Olsson, Birgit; Sun, Xiao‐Feng

doi:10.1186/1748-717x-8-281

Cited by 15 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As showed for other cancer types [19, 27, 40, 41, 45], we observed livin localized in both cytoplasm and nuclei. However, none of the previous observations described a significant difference in livin distribution between adenomas and carcinomas.…”

Section: Discussionsupporting

confidence: 86%

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors

et al. 2016

View full text Add to dashboard Cite

Relative livin mRNA expression was significantly higher in ACC than in ACA and NAG (0.060 ± 0.116 vs 0.004 ± 0.014 and 0.002 ± 0.009, respectively, p < 0.01), being consistently higher in tumors than in adjacent NAG and isoform β more expressed than α. No significant differences in CASP3, XIAP and DIABLO levels were found among these groups. In immunohistochemistry, livin was localized in both cytoplasm and nuclei.The ratio between cytoplasmic and nuclear staining was significantly higher in ACC (1.51 ± 0.66) than in ACA (0.80 ± 0.35) and NAG (0.88 ± 0.27; p < 0.0001). No significant correlations were observed between livin expression and histopathological parameters or clinical outcome. In NCI-H295R cells, the livin overexpression slightly reduced the activation of CASP3, but did not correlate with cell viability.In conclusion, livin is specifically over-expressed in ACC, suggesting that it might be involved in adrenocortical tumorigenesis and represent a new molecular marker of malignancy.

show abstract

Section: Discussionsupporting

confidence: 86%

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…By contrast, the ability of anti-livin antibody to detect colon cancer was apparently low throughout all stages, which was consistent with the relatively lower expression of the livin protein in colon cancer (22).…”

Section: Discussionsupporting

confidence: 68%

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

Hosono

Goto

Kobayashi

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Autoantibodies against cancer-related antigens may be detected in the sera of patients with various types of cancer, although their clinical utility has not yet been established. In this study, we aimed to demonstrate the diagnostic relevance of autoantibody detection against inhibitor of apoptosis protein (IAP) family members in colon cancer, as compared to anti-p53 antibody, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9. We established an ELISA system using original recombinant proteins of IAP family members (survivin, livin and X-linked IAP) and measured the expression levels in the sera of 62 healthy donors, 250 patients with colon polyps (adenoma) and 176 patients with colon cancer. When the cutoff value was set as the mean value + 2 standard deviations in healthy donors, anti-survivin exhibited the highest positivity rate (24.4%) among IAP autoantibodies in cancer patients. Furthermore, the anti-survivin antibody exhibited a high positivity rate in early-stage carcinoma and adenoma. In the combination assay, reflecting the significantly high positivity rate of CEA in stage IV tumors, the positivity rate was highest when combining the detection of anti-survivin antibody and CEA in cancer patients (50.0%), indicating that this combination may not be useful for the diagnosis of early-stage cancers. By contrast, reflecting the complete independence of anti-survivin and anti-p53 antibodies, the combination of detecting these two antibodies resulted in the highest positivity rate (35.6%) in early-stage disease (stage 0-I). These results suggest that the combined measurement of anti-survivin and anti-p53 antibodies may be useful for the detection of early-stage colon cancer.

show abstract

“…In patients with rectal cancer, Livin expression was associated with unfavorable OS independent of TNM stage, local and distant recurrence, grade of differentiation, gender, and age. 22 In squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder, BIRC7 expression was an independent poor prognostic factor in terms of postoperative survival. 7 Although the oncogenic effects of BIRC7 have been reported in prostate cancer, its prognostic value has not been explored.…”

Section: Discussionmentioning

confidence: 94%

High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer

Yang

Sun

et al. 2018

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: BIRC7, which encodes Baculoviral inhibitor of apoptosis (IAP) repeat-containing protein 7, is an oncogene in multiple types of cancer. In this study, we examined the association between BIRC7 expression and the clinicopathological characteristics of prostate cancer, the independent prognostic value of BIRC7 in terms of recurrence-free survival, and the molecular mechanisms of its dysregulation.Methods:Data mining was performed using data from The Cancer Genome Atlas. The patients were divided into high and low BIRC7 expression groups according to the Youden index determined by receiver operating characteristic curves for recurrence. Subgroup analysis was performed according to T stages and Gleason score.Results: BIRC7 was significantly upregulated in prostate cancer tissues (N = 497) than in normal prostate tissues (N = 52). High BIRC7 expression group had lower ratios of overall response rate and medium-grade (Gleason score 6-7) tumors and higher proportions of nodal invasion and recurrence after surgery. Although Kaplan-Meier curves showed that high BIRC7 expression was generally associated with poor recurrence-free survival, the following subgroup analysis only confirmed the association in T3/T4 and medium-grade tumors. Multivariate analysis showed that BIRC7 expression was not an independent indicator of recurrence-free survival in T2 or high-grade tumors, but was independently associated with poor recurrence-free survival in T3/T4 tumors (hazard ratio: 4.249, 95% confidence interval: 1.563-11.546, P = .005) and in medium-grade tumors (hazard ratio: 6.041, 95% confidence interval: 1.763-20.703, P = .004). DNA amplification was associated with significantly upregulated BIRC7 expression. There was also a weak negative correlation between BIRC7 expression and its DNA methylation (Pearson r = −0.23).Conclusion:Based on these findings, we infer that BIRC7 upregulation might serve as a valuable biomarker of increased recurrence risk in advanced T stages and medium-grade prostate cancer. Its expression is at least regulated by both copy number alteration and DNA methylation.

show abstract

Livin expression is an independent factor in rectal cancer patients with or without preoperative radiotherapy

Cited by 15 publications

References 38 publications

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors

Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma

High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer

Contact Info

Product

Resources

About